Company Filing History:
1 out of 34 
1 out of 43 Years Active: 2021
Title: Eri Atsuyama: Innovator in Cancer Research
Introduction
Eri Atsuyama is a prominent inventor based in Nagano, Japan. She has made significant contributions to the field of cancer research, particularly in the development of tumor antigen peptides. Her work aims to enhance the prevention and treatment of cancer, showcasing her dedication to advancing medical science.
Latest Patents
Atsuyama holds a patent for a tumor antigen peptide. The objective of this patent is to provide a peptide that is specifically presented on cancer and cancer stem cells. This innovation includes a pharmaceutical composition that is useful for the prevention and treatment of cancer, containing the peptide as an active ingredient. The patent has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, along with a polynucleotide encoding the peptide. This composition is designed to induce cytotoxic T lymphocytes (CTLs) for effective cancer treatment.
Career Highlights
Throughout her career, Eri Atsuyama has worked with esteemed institutions such as Sapporo Medical University and Medical & Biological Laboratories Co., Ltd. Her experience in these organizations has allowed her to collaborate with leading experts in the field, further enhancing her research capabilities.
Collaborations
Atsuyama has collaborated with notable colleagues, including Toshihiko Torigoe and Hironori Otaka. These partnerships have contributed to her innovative research and the development of her patent.
Conclusion
Eri Atsuyama's work in cancer research exemplifies her commitment to improving treatment options for patients. Her innovative patent and collaborations with esteemed colleagues highlight her significant contributions to the field.